The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.
Open accessAbstract
Tumor necrosis factor type alpha (TNF-alpha) inhibits endothelial cell proliferation in vitro. Basal cell growth (in the absence of exogenously added growth factor) and fibroblast growth factor (FGF)-stimulated cell proliferation are inhibited in a dose-dependent manner from 0.1 to 10 ng/ml with half-maximal inhibition occurring at 0.5-1.0 ng of TNF-alpha per ml. Bovine aortic and brain capillary endothelial and smooth muscle cells are similarly affected. TNF-alpha is a noncompetitive antagonist of FGF-stimulated cell proliferation. Its action on endothelial cells is reversible and noncytotoxic. Surprisingly, TNF-alpha does not seem to inhibit endothelial cell proliferation in vivo. In the rabbit cornea, even a high dose of TNF-alpha (10 micrograms) does not suppress angiogenesis induced by basic FGF. On the contrary, in this model system TNF-alpha stimulates neovascularization. The inflammatory response that is seen in the cornea after TNF-alpha implantation suggests that the angiogenic properties of this agent may be a consequence of leukocyte infiltration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An endotoxin-induced serum factor that causes necrosis of tumors
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., & Williamson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.9.3666 · Cited by 4,532
Voyta, J. C., Via, D. P., Butterfield, C. E., & Zetter, B. R. (1984) · The Journal of cell biology · doi:10.1083/jcb.99.6.2034 · Cited by 1,239
Cited by
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809
Regulation of Vascular Endothelial Growth Factor Expression in Cultured Keratinocytes.
Frank, S., Hübner, G., Breier, G., Longaker, M. T., Greenhalgh, D. G., & Werner, S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.21.12607 · Cited by 764
Cachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue Remodeling
Vlassara, H., Brownlee, M., Manogue, K. R., Dinarello, C. A., & Pasagian, A. (1988) · Science · doi:10.1126/science.3259727 · Cited by 597
Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression
Vona-Davis, L., & Rose, D. P. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-06-0068 · Cited by 496
Obesity, adipocytokines, and insulin resistance in breast cancer
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00142.x · Cited by 460
MORI, R., KONDO, T., OHSHIMA, T., ISHIDA, Y., & MUKAIDA, N. (2002) · The FASEB Journal · doi:10.1096/fj.01-0776com · Cited by 250
Enhancement of experimental metastasis by tumor necrosis factor.
Orosz, P., Echtenacher, B., Falk, W., Rüschoff, J., Weber, D., & Männel, D. N. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.5.1391 · Cited by 198
Risau, W. (1990) · Progress in Growth Factor Research · doi:10.1016/0955-2235(90)90010-h · Cited by 145
Self-citationImmune Aspects of Wound Repair
Barbul, A. (1990) · Clinics in Plastic Surgery · doi:10.1016/s0094-1298(20)30618-0 · Cited by 111
Ito, A., Sato, T., Iga, T., & Mori, Y. (1990) · FEBS Letters · doi:10.1016/0014-5793(90)81127-a · Cited by 100
The effect of topical tripeptide-copper complex on healing of ischemic open wounds
Canapp, S. O., Farese, J. P., Schultz, G. S., Gowda, S., Ishak, A. M., Swaim, S. F., Vangilder, J., Lee‐Ambrose, L., & Martin, F. G. (2003) · Veterinary Surgery · doi:10.1111/j.1532-950x.2003.00515.x · Cited by 68
Etanercept decreases tumor necrosis factor‐α activity in chronic wound fluid
Cowin, A. J., Hatzirodos, N., Rigden, J., Fitridge, R., & Belford, D. A. (2006) · Wound Repair and Regeneration · doi:10.1111/j.1743-6109.2006.00141.x · Cited by 43
The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI)
Vadhan, J. D., & Speth, R. C. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107684 · Cited by 42
Refractory ulcers: The role of tumor necrosis factor–α
Weinstein, D. A., & Kirsner, R. S. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.08.004 · Cited by 33
Anti-angiogenic effects of mangiferin and mechanism of action in metastatic melanoma
Delgado-Hernández, R., Hernández-Balmaseda, I., Rodeiro-Guerra, I., Cesar Rodriguez Gonzalez, J., De Wever, O., Logie, E., Declerck, K., Pérez-Novo, C., & Vanden Berghe, W. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000647 · Cited by 29
Okoro, E. U. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126236 · Cited by 18
Metadata
- Authors
- Fràter-Schröder, M., Risau, W., Hallmann, R., Gautschi, P., & Böhlen, P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1987-08
- Volume
- 84
- Issue
- 15
- Pages
- 5277-5281
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1987399881
- Cited by
- 703
- References
- 2
- FWCI
- 12.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
